Medilink Therapeutics (suzhou) Co., Ltd.

This early-stage trial is testing a new drug called YL201 combined with an immunotherapy (serplulimab) and sometimes chemotherapy in people with advanced solid tumors. The study has two parts: first, finding the safest dose, and then seeing if the combination shrinks tumors. Abou…

This Phase 3 study compares a new drug called YL201 to the standard treatment topotecan in 438 adults with relapsed small cell lung cancer. The goal is to see if YL201 helps people live longer. Participants receive either YL201 by infusion every three weeks or topotecan by inject…

This early-stage trial tests a new drug called YL202 in about 80 people with advanced lung or breast cancer that has not responded to standard treatments. The drug is given by IV every three weeks. The main goal is to check safety and find the right dose, not yet to prove it work…

This study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.